Twist Bioscience, Seismic Bio partner to discover bispecific antibodies

By The Science Advisory Board staff writers

August 4, 2020 -- Twist Bioscience and Seismic Bio have formed a partnership to discover and optimize antibodies to high-value immuno-oncology targets.

Under the terms of the deal, Twist Bioscience division Twist Biopharma will use its Hyperimmune Libraries -- two human antibody libraries focused on the heavy chain complementary-determining region 3 (CDR3) loop diversity involved in antigen recognition -- to identify antibodies that bind to the specified immuno-oncology targets. Seismic Bio will then use these monoclonal antibodies as building blocks to create bispecific antibody therapeutics, according to the companies.

In addition, Seismic Bio will pay fees to Twist for technology activity and milestones for all compounds discovered through the partnership.

Takeda, Twist partner on biologics discovery
Twist Bioscience and Takeda Pharmaceutical have formed a partnership for access to Twist's proprietary phage display libraries for the discovery of antibodies...
Twist, Serimmune identify SARS-CoV-2 antibody therapies
Twist Bioscience has joined forces with Serimmune to identify and evaluate SARS-CoV-2 therapeutic antibody candidates.
Twist's SARS-CoV-2 quality controls added to FDA materials
Twist Bioscience's synthetic SARS-CoV-2 RNA quality controls for the development, verification, and validation of diagnostic tests for SARS-CoV-2 are...
Twist Bioscience partners with Miroculus on clinical products
Synthetic biology company Twist Bioscience announced on February 25 that it has initiated a collaboration with digital microfluidics developer Miroculus...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter